Adalimumab biosimilar (Danhong Pharma)

阿达木单抗生物类似药 (山东丹红制药)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAdalimumab biosimilar (Danhong Pharma)

Drug Alias Name重组抗肿瘤坏死因子-α（TNF-α）全人源单克隆抗体 (山东丹红制药)阿达木单抗生物仿制药 (山东丹红制药)BC-002

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsArthritis, RheumatoidSpondylitis, Ankylosing

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaPhase 3 Clinical

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsSpondylitis, Ankylosing

Inactive IndicationsArthritis, Rheumatoid

ATC CodeL04AB04